Even in a downturn, a small IPO window could open later this year, according to a Goodwin partner and co-chair of the firm’s Capital Markets practice. Read the Protocol article here.
Related Content
- Alert19 July 2024
Historic New Listing Rules Adopted for the UK
- NewslettersJune 27, 2024
FDIC Approves Final Revised Rule to Strengthen Resolution Planning for Large Banks
- NewslettersJune 13, 2024
OCC Revises Comptroller’s Handbook Booklet for Retail Nondeposit Investment Products
- NewslettersJune 6, 2024
CFPB Launches Process to Recognize Open Banking Standards
- NewslettersMay 23, 2024
CFPB Takes Action to Ensure Consumers Can Dispute Charges and Obtain Refunds on Buy Now, Pay Later Loans
- AlertMay 20, 2024
New Proxy Voting Reporting Requirements For Investment Managers For 2023-24 Annual Meeting Season
- NewslettersMay 17, 2024
Supreme Court Upholds Constitutionality of CFPB Funding Mechanism
- NewslettersMay 9, 2024
FDIC, OCC, and FHFA Issue Notice Regarding Proposed Rulemaking on Incentive-Based Compensation Arrangements
- Speaking EngagementsOctober 14, 2024
Proxy Disclosure & 21st Annual Executive Compensation Conferences 2024
- Press ReleaseJuly 8, 2024
Goodwin Represents the Underwriters For Taysha Gene Therapies $75 Million Public Offering
- Press ReleaseJune 28, 2024
Entrada Therapeutics Closes $100 Million Registered Direct Offering
- Press ReleaseJune 13, 2024
Rapport Therapeutics Completes $174.4 Millon Initial Public Offering and Concurrent Private Placement
- Awards and RankingsJune 13, 2024
The Legal 500 US 2024 Recognizes 44 Goodwin Practices and 186 Lawyers
- Press ReleaseJune 12, 2024
Goodwin Represents the Underwriters For Royalty Pharma’s $1.5 Billion Senior Unsecured Notes Public Offering
- Awards and RankingsJune 6, 2024
Chambers USA 2024 Recognizes Goodwin Practices and Lawyers for Exceptional Client Service
- Press ReleaseMay 21, 2024
Pheon Therapeutics Completes $120 million Series B